Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SAR443820 in Healthy Adults
NCT05795907Phase 1Completed
- Sponsor
- Sanofi
- Start
- Nov 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing SAR443820 with Placebo (2 arms). Primary endpoint: Number of participants with adverse events. Started Nov 2020; status: completed.
02
Drugs
oditrasertib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05795907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05795907.